Gilead Sciences: Investor-Grade Deep Dive Research Report

Prepared by: Ada Cockpit
Date: March 11, 2026
Report Type: Comprehensive Investment Research & Ada Patient Finder Analysis

Executive Summary

Company Overview

Gilead Sciences, Inc. (NASDAQ: GILD) is a leading biopharmaceutical company headquartered at 333 Lakeside Drive, Foster City, California. Founded on June 22, 1987, by Michael L. Riordan, Gilead has evolved from an antiviral-focused startup into a global leader in HIV, viral hepatitis, oncology, and inflammatory diseases. The company employs more than 17,000 professionals worldwide and operates across more than 35 countries.

Key Financial Metrics (FY 2025)

Revenue Mix by Segment (2025)

Revenue Growth Trajectory

Strategic Position

Gilead dominates the global HIV treatment market with Biktarvy holding over 52% market share in the United States, contributing $14.3 billion in 2025 sales (+7% YoY). The company's strategic pillars include:

1. HIV Franchise Expansion: Twice-yearly lenacapavir (Yeztugo) for PrEP launched June 2025 with 100% efficacy in PURPOSE trials, targeting underserved populations.
2. Oncology Growth: Trodelvy secured first-line triple-negative breast cancer (TNBC) indications with 38% risk reduction vs. chemotherapy; $1.4B in 2025 sales (+6%).
3. Cell Therapy Leadership: Arcellx acquisition ($7.8B announced February 2026) adds anito-cel CAR-T for multiple myeloma, complementing Yescarta/Tecartus portfolio.
4. Liver Disease Innovation: Livdelzi (seladelpar) for primary biliary cholangitis launched 2025, tracking above expectations.

Growth Trajectory and Medium-Term Targets

• 2026 Guidance: Product sales of $29.6–$30.0 billion; non-GAAP EPS of $8.45–$8.85
• Base Business Growth: 4–5% annually, driven by HIV portfolio (+6% in 2025) and liver disease (+6% in 2025)
• Long-Term Commitment: $32 billion in U.S.-based R&D and manufacturing through 2030, creating 3,000+ jobs
• Pipeline Momentum: 53 programs (25 in Phase 3) targeting HIV, oncology, inflammation, and virology

Top 5 Product Portfolio Highlights

Product	Indication	2025 Revenue	Growth	Strategic Importance
Biktarvy	HIV-1 treatment (STR)	$14.3B	+7%	Backbone of HIV franchise; >52% U.S. market share; LOE 2033–2036
Lenacapavir (Yeztugo/Sunlenca)	HIV PrEP & treatment	Ramp phase	New launch	First twice-yearly option; 100% PrEP efficacy; $4B peak potential
Descovy	HIV treatment & PrEP	$2.8B	+31%	PrEP expansion driver; TAF safety profile; LOE ~2027
Trodelvy	Metastatic TNBC, HR+/HER2- BC	$1.4B	+6%	First-line TNBC approval pending H2 2026; $3-4B peak potential
Yescarta + Tecartus	CAR-T for LBCL, FL, MCL	$1.8B (combined)	-7%	Cell therapy leadership; anito-cel acquisition strengthens MM position

Key Investment Highlights

Ada Patient Finder: High-Value Opportunities

The Ada Patient Finder analysis evaluated Gilead's portfolio for compatibility with symptom-assessment-driven case finding. Three high-value opportunities were identified where diagnostic delay, underdiagnosis, and symptom specificity align with Ada's capabilities:

Drug	Indication	Fit Score	Undiagnosed Eligible (U.S.)	Diagnostic Delay	Per-Patient Revenue
Livdelzi	Primary biliary cholangitis	8/10	4,200–7,800 patients	1–3 years	~$100,000/year
Vemlidy	Chronic hepatitis B	7/10	165,000–330,000 patients	5–15 years (asymptomatic)	~$8,000/year
Trodelvy	Metastatic TNBC (screening navigation)	6/10	N/A (screening-driven)	Moderate (underscreened populations)	~$175,000/year

Livdelzi (PBC): Top Ada Opportunity

Primary biliary cholangitis (PBC) affects ~105,000 Americans, predominantly women, but 20–30% remain undiagnosed for years. Patients experience debilitating itching and fatigue—often dismissed as stress or menopause—with a median diagnostic delay of 1–3 years. Livdelzi, the first treatment to address both liver inflammation and pruritus, could benefit ~21,000–26,000 U.S. patients currently on inadequate therapy.

Ada's value proposition: Flag persistent pruritus + fatigue in women >40 and prompt ALP/AMA testing. With per-patient net revenue of ~$100,000/year, each Ada-surfaced case represents significant clinical and commercial value. Estimated Year 1 revenue impact: $2.4–6.4M (at 8% share).

Competitive Positioning

Peer Valuation Comparison (March 2026)

Company	Market Cap	2025 Revenue	Revenue Growth	Trailing P/E	Key Franchise
Gilead Sciences	$184.4B	$29.4B	+2%	21.6x	HIV (72% of sales)
AbbVie	~$280B	~$56B	+4%	~35x	Immunology (Skyrizi, Rinvoq)
Amgen	~$165B	~$28B	+6%	~18x	Oncology/Inflammation
Bristol Myers Squibb	~$110B	~$46B	+1%	~10x	Oncology (Opdivo, Revlimid LOE)
Vertex Pharmaceuticals	~$120B	~$10B	+12%	~30x	Cystic Fibrosis (90% of sales)

Gilead's Positioning: Mid-range valuation (21.6x P/E) reflecting moderate growth (+2% 2025) and Biktarvy patent cliff risk (2033–2036), but strong HIV franchise dominance and lenacapavir innovation offset near-term headwinds. Valuation premium vs. BMS (10x P/E, Revlimid LOE challenges) but discount vs. Vertex (30x P/E, 12% growth, CF monopoly).

Major Risks and Challenges

1. Biktarvy Patent Cliff (2033–2036)

Primary composition-of-matter patents expire 2033, with generic entry delayed to November 8, 2036 (U.S.) via settlements with Lupin, Cipla, Laurus Labs. $14.3B revenue at risk represents 49% of HIV revenue and 48% of total product sales. Expected 70–80% generic erosion upon LOE.

Mitigation: Gilead developing 7 new HIV treatments (12 molecules, 11 combinations) through 2033, including lenacapavir combos (BIC/LEN, GS-3242/LEN, long-acting injectables). Success depends on patient/provider adoption of twice-yearly regimens vs. established daily oral therapy.

2. HIV Concentration Risk

HIV accounts for 72% of total product sales ($20.8B of $28.9B). Diversification into oncology (11%) and liver disease (11%) insufficient to offset HIV headwinds from patent cliffs, competitive long-acting injectables, and pricing pressure.

3. Regulatory and Pricing Pressure

• Medicare IRA Drug Price Negotiation: Biktarvy, Descovy, Genvoya may face negotiated pricing starting 2026–2029; estimated 10–25% price reductions → $500M–1.5B annual revenue risk
• Medicare Part D Redesign: Already impacted 2025 revenue by $900M for HIV portfolio due to increased manufacturer liability
• 340B Program Expansion: Hospitals purchasing at 50–70% discounts represent growing share; 5–10% of U.S. revenue affected

4. Competitive Pressures

• ViiV Healthcare: Cabenuva (monthly injectable) and Apretude (bimonthly PrEP) offer dosing convenience vs. daily oral Biktarvy
• Oncology ADCs: Enhertu (Daiichi Sankyo/AstraZeneca) dominates HER2-low breast cancer; potential TNBC overlap with Trodelvy
• CAR-T (Multiple Myeloma): BMS Abecma and J&J Carvykti established; Gilead's anito-cel must demonstrate differentiated safety/efficacy

2026 Guidance and Growth Outlook

FY 2026 Guidance (Announced February 10, 2026)

Metric	2026 Guidance	vs. 2025	Street Consensus
Product Sales	$29.6–30.0B	+2–4%	$30.2B
Base Business (ex-Veklury)	$29.0–29.4B	+4–5%	—
Non-GAAP Diluted EPS	$8.45–8.85 (mid $8.65)	+6%	$8.76
Non-GAAP Operating Income	$13.8B	47% margin	—

Analyst Reaction: Guidance fell short of Street consensus, prompting a ~$4.45 share price decline to $147.23 on February 10, 2026. Management highlighted growth drivers (HIV +6%, liver +6%, lenacapavir ramp, Trodelvy first-line approval pending) but noted Medicare Part D headwinds and Veklury decline.

Growth Scenarios (2026–2030)

Scenario	Key Assumptions	2030 Revenue	2030 Market Cap
Bull Case	Lenacapavir $4B peak; Trodelvy $5B; anito-cel 30% MM share; BIC/LEN transitions 30-40% Biktarvy	$42B	$220–250B
Base Case	Lenacapavir $2-3B peak; Trodelvy $3.5B; anito-cel 20% MM share; BIC/LEN transitions 20-25%	$37B	$200–230B
Bear Case	Lenacapavir underperforms ($1-1.5B); Trodelvy delayed; anito-cel fails to differentiate; early cliff	$33B	$165–185B

Investment Thesis Summary

Conclusion

Gilead Sciences stands at a critical juncture: dominant in HIV (52% U.S. Biktarvy market share, $20.8B HIV revenue) but facing a $14.3B patent cliff (2033–2036) and concentration risk (72% of sales from HIV). The company's response—7 new HIV treatments including twice-yearly lenacapavir, oncology expansion (Trodelvy first-line TNBC, anito-cel CAR-T), and liver disease innovation (Livdelzi PBC)—positions it for 3-5% annual growth through 2030 in the base case.

Key investment decision factors:

1. Lenacapavir adoption trajectory (PrEP + treatment): Can Gilead convert patients from daily oral to twice-yearly injectables at scale?
2. Trodelvy first-line approval and uptake (H2 2026 FDA decision): Will payers reimburse $200K/year ADC vs. chemotherapy without mature OS data?
3. Anito-cel differentiation (FDA PDUFA Dec 2026): Can Gilead capture 20-30% MM CAR-T market share vs. Carvykti/Abecma?
4. Pricing environment: How severe will Medicare IRA negotiation + Part D redesign impact be on Biktarvy/Descovy/Genvoya (2027–2029)?
5. Pipeline replacement math: Will BIC/LEN + GS-3242/LEN + long-acting combos collectively replace $14.3B Biktarvy revenue pre-LOE?

At $184.4B market cap, 21.6x P/E, and 6.3x P/S, Gilead trades at mid-range vs. biopharma peers, reflecting balanced risk/reward. Bull case ($220-250B by 2030) hinges on lenacapavir + Trodelvy + anito-cel execution. Bear case ($165-185B) materializes if pricing pressure accelerates, lenacapavir underperforms, and Biktarvy cliff arrives early via competitive dynamics.

For Ada Health: Gilead's portfolio presents high-value Patient Finder opportunities in Livdelzi (PBC, 8/10 fit) and Vemlidy (HBV, 7/10 fit), with estimated Year 1 revenue impact of $2.8–7.6M. Livdelzi case finding (pruritus + fatigue in women >40 → ALP/AMA testing) is the top near-term priority, scalable to $20-40M annually at 10M MAU penetration.

References

Note: Full 96-source reference list available in the complete markdown report. This HTML summarizes key citations for investor presentation purposes.